United States-based pharmaceutical giant Johnson and Johnson (J&J) has received the emergency use approval for its Covid-19 vaccine in India, informed Union Health Minister Mansukh Mandaviya on Saturday (6 August).
J&J's Covid-19 vaccine is the fifth jab to be approved for emergency-use in India.
Earlier, the Drug Controller General of India (DCGI) had approved Serum Insitute of India's Covishield, Bharat Biotech's Covaxin, Russian Sputnik V vaccine and US-based Moderna's Covid jab.
"India expands its vaccine basket! Johnson and Johnson’s single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," Mandaviya said in a tweet.
In a statement issued on Friday (6 August), the US pharma major said that it had submitted its emergency use approval application to the Indian drug regulator on Thursday (5 August).
J&J has partnered with the Indian biotech firm Biological E for the production of its vaccine in India.
J&J's vaccine developed by Janssen Pharmaceutical Companies of Johnson & Johnson comprises one shot and reportedly found to have 85.4 per cent efficacy against severe disease and 93.1 per cent against hospitalisation.
Comments ↓
An Appeal...
Dear Reader,
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.
The embedded tweet could not be found…
